The Next Generation of Coronavirus Vaccines Won’t Come as Quickly

April 23, 2021

(Axios) – A flood of cash from Operation Warp Speed helped coax a slew of biotech companies into the race for a coronavirus vaccine, but the incentives to keep working on new competitors won’t be nearly as strong. Why it matters: That initial flood of cash worked — it delivered multiple, highly effective vaccines in record time. In other disease areas, though, second- and third-generation vaccines usually become the dominant products. And the first COVID-19 vaccines aren’t necessarily a great fit for the whole world.